Wang Zhen, Zheng Yisheng, Fang Zhenjian
Department of Respiratory Medicine, Ningbo NO, 7 Hospital, China.
Department of Respiratory and Critical Care Medicine, Fuzong Clinical College of Fujian Medical University, Fuzhou General Hospital, China.
Rev Assoc Med Bras (1992). 2018 Mar;64(3):230-233. doi: 10.1590/1806-9282.64.03.230.
The current study aimed to investigate the clinical efficacy of paclitaxel combined with avastin for non-small cell lung cancer (NSCLC) patients diagnosed with malignant pleural effusion (MPE).
Total of 33 patients diagnosed with NSCLC as well as malignant pleural effusion were included. All of them received paclitaxel (175 mg/m2) and avastin (5 mg/kg). Clinical efficacy was evaluated using the total response rate, overall survival, progression-free survival and changes in MPE volume. Adverse events and rates of toxicities were examined as well.
The total response rate reached 77% while the overall survival and the median progression-free survival were respectively 22.2 months and 8.4 months. Toxicities of grade 3-4 consisted of neutropenia in 57% of patients, anemia in 17% of them, febrile neutropenia in 11%, as well as anorexia in 7%. No treatment-correlated deaths were found.
Paclitaxel combined with avastin decreased MPE volume and increased survival rate of NSCLC patients via inhibiting vascular endothelial growth factor expression.
本研究旨在探讨紫杉醇联合阿瓦斯汀对诊断为恶性胸腔积液（MPE）的非小细胞肺癌（NSCLC）患者的临床疗效。
纳入33例诊断为NSCLC伴恶性胸腔积液的患者。所有患者均接受紫杉醇（175mg/m²）和阿瓦斯汀（5mg/kg）治疗。使用总缓解率、总生存期、无进展生存期和MPE体积变化评估临床疗效。同时检查不良事件和毒性发生率。
总缓解率达到77%，总生存期和中位无进展生存期分别为22.2个月和8.4个月。3-4级毒性包括57%的患者出现中性粒细胞减少，17%的患者出现贫血，11%的患者出现发热性中性粒细胞减少，7%的患者出现厌食。未发现与治疗相关的死亡病例。
紫杉醇联合阿瓦斯汀通过抑制血管内皮生长因子表达减少MPE体积并提高NSCLC患者的生存率。
